123I-MIBG Uptake or Washout at Baseline as Predictor of Differential Treatment Effect
| Study | Therapy | No. of patients | Follow-up | Design | Results |
| Suwa et al. (38) | Bisoprolol | 45 | 8 mo | Uncontrolled | Baseline HMR associated with “response,” defined as both reverse remodeling and improvement in NYHA class |
| Choi et al. (15) | Carvedilol | 11 | 12 mo | RCT | Inverse correlation between baseline WOR and change in LVEF |
| Gerson et al. (18) | Carvedilol | 22 | 7 mo | Uncontrolled | No relationship between baseline HMR and change in LVEF |
| Yamazaki et al. (16) | β-blockers | 40 | 6 mo | Uncontrolled | Lower mean extent and severity uptake scores at baseline in patients with change in LVEF of >10% |
RCT = randomized controlled trial; WOR = washout rate for 123I-MIBG.